Publications
Detailed Information
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.contributor.author | Cho, Byoung Chul | - |
dc.contributor.author | Kang, Jin Hyoung | - |
dc.contributor.author | Han, Ji-Youn | - |
dc.contributor.author | Min, Young Joo | - |
dc.contributor.author | Park, Keunchil | - |
dc.date.accessioned | 2020-04-27T11:03:44Z | - |
dc.date.available | 2020-04-27T11:03:44Z | - |
dc.date.created | 2019-06-26 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.citation | Lung Cancer, Vol.122, pp.234-242 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.other | 76823 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165235 | - |
dc.description.abstract | Objectives: To investigate the efficacy and safety of nivolumab in Korean patients with stage IIIB/IV or recurrent non-small-cell lung cancer (NSCLC) who failed platinum-based chemotherapy. Materials and methods: In this multicenter, open-label, Phase II study, 100 patients with stage IIIB or IV squamous (n = 44) or non-squamous (n = 56) NSCLC received nivolumab 3 mg/kg every 2 weeks for 6 weeks per treatment cycle. Patients continued treatment until disease progression or intolerable adverse events (AEs), and then entered a follow-up phase. The primary efficacy endpoint was the centrally assessed objective response rate (ORR). Results: The ORR was 20.0% (95% confidence interval [CI]: 13.3-28.9%) in the total population, 15.9% (7/44 patients; 95% CI: 7.9-29.4%) in patients with squamous NSCLC, and 23.2% (13/56 patients; 95% CI: 14.1-35.8%) in patients with non-squamous NSCLC. Median overall survival was 13.9 (95% CI: 10.8-18.5) months in the total population, 12.3 (95% CI: 8.2-18.5) months in squamous NSCLC, and 16.3 (95% CI: 10.8,) months in non-squamous NSCLC. Median progression-free survival was 2.8 (95% CI: 1.4-5.7), 2.6 (95% CI: 1.3-5.7), and 5.3 (95% CI: 1.4-7.1) months in the total, squamous, and non-squamous NSCLC populations, respectively. The median duration of response was 11.7 (95% CI: 5.6,), 12.0 (95% CI: 4.8,-), and 12.1 (95% CI: 3.0,-) months in the total, squamous, and non-squamous NSCLC populations, respectively. The most frequent AEs were decreased appetite, dyspnea, and cough in 43 (43.0%), 32 (32.0%), and 29 (29.0%) patients, respectively. The most common Grade >= 3 AE was pneumonia, occurring in 7.0% of patients. Common treatment -related AEs included decreased appetite (14.0%) and pruritus (6.0%), neither of which was Grade >= 3. Conclusion: The efficacy and safety of nivolumab in Korean patients with advanced or recurrent squamous or non-squamous NSCLC are consistent with previous reports. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.identifier.doi | 10.1016/j.lungcan.2018.05.023 | - |
dc.citation.journaltitle | Lung Cancer | - |
dc.identifier.wosid | 000440769900038 | - |
dc.identifier.scopusid | 2-s2.0-85049013316 | - |
dc.citation.endpage | 242 | - |
dc.citation.startpage | 234 | - |
dc.citation.volume | 122 | - |
dc.identifier.sci | 000440769900038 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | ANTI-PD-1 ANTIBODY | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | 2ND-LINE TREATMENT | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | BMS-936558 | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | Nivolumab | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | Programmed cell death-1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.